Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the …
Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the …
A pivotal efficacy study and a separate G-CSF reduction trial could answer different questions, but market projections remain …
The investigational triple agonist matched semaglutide on average glucose reduction and delivered roughly twice the percentage weight loss …
Three portfolio companies have entered first-in-human trials in oncology and anticoagulation, but the venture-biotech model will be judged …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
Latest clinical updates highlight cutting-edge oncology treatments, AI advancements in drug development, and efforts to accelerate trial startup …
Already a subscriber? Log in